Novo Nordisk Partners with Aspen to Support Insulin Production in Africa
Deal aims to provide diabetes treatment to patients across the continent.
In an effort to provide life-saving treatment to people living with diabetes across the African continent, Novo Nordisk have officially announced a partnership with Aspen. As per the agreement, Aspen will focus on producing Insulin from its facilities in South Africa. Reportedly, the partnership will result in a production of 16 million vials of insulin, equivalent to the yearly consumption of 1.1 million people next year. Additionally, the company stated that this will increase to 4.1 million by 2026.
“We firmly believe that access to quality healthcare is a fundamental human right,” said Katrine DiBona, corporate VP, global public affairs and sustainability, Novo Nordisk. "We are committed to providing affordable human insulin to ensure access to quality treatments for even more people with diabetes in the African continent. At the same time, it is equally important for us that we are doing it in a sustainable way by focusing on local production.”
Reference: Novo Nordisk announces new partnership to supply human insulin to millions of people living with diabetes in the African continent. Novo Nordisk. September 19, 2023. Accessed September 20, 2023. https://www.novonordisk.com/news-and-media/latest-news/new-partnership-to-supply-human-insulin.html
